Almonertinib after chemoradiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give informed consent
- Have stage III non-small cell lung cancer that cannot be removed with surgery
- Your tumor must have specific EGFR mutations (Ex19Del or L858R) found by an approved EGFR blood/tissue test
- You must have finished standard chemoradiation: at least 2 rounds of platinum chemo and total radiation dose 54–66 Gy, finishing within 6 weeks
- Your cancer must not have grown during or after the chemoradiation (no progression)
- You must have good overall health for trial participation (good energy/strength and enough organ function, and no significant ongoing side effects)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
This trial tests if adding gumarontinib to a third-generation EGFR-targeted drug can help people with advanced non-small cell lung cancer whose cancer grew while on an EGFR-TKI and has a certain change (MET amplification). The goal is to see if this combination can overcome resistance.
This trial tests a combination of two targeted drugs (a third-generation EGFR-TKI and anlotinib) as maintenance therapy for people with non-small cell lung cancer that has changed into small cell cancer after resistance to EGFR-TKI therapy. It may help control the cancer longer.
This trial tests a targeted pill (Firmonertinib) combined with chemotherapy before surgery for people with early to mid-stage non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.